United StatesBreaking News

Jim Caron, Morgan Stanley Investment Management portfolio solutions CIO, says this is a stock pickers market, but it's still very important to have a diversified portfolio. He speaks on "Bloomberg Surveillance."

Kaos Capital, an activist hedge fund based in Miami, has acquired a 4.9% stake in BioRestorative Therapies (NASDAQ:BRTX) and plans to push the biotechnology company to pivot toward artificial intelligence opportunities.

Diana Shipping (NYSE:DSX) sweetened its all-cash hostile bid to acquire rival dry bulk carrier Genco Shipping & Trading (NYSE:GNK) for $1.433 billion, escalating pressure on the target company's board while prolonging its concurrent proxy fight.

G-III Apparel Group (NYSE:GIII) announced that its board of directors has declared a quarterly cash dividend of $0.10 per share, continuing its programmatic capital return strategy for the current fiscal period.

Edward Yardeni, president at Yardeni Research, says the basic thrust of the market is higher as he touts "FEMO" or the "fabulous earnings momentum" he sees driving a melt up in stocks.

Scorpio Tankers (NYSE:STNG) agreed to sell four of its LR2 product tankers for an aggregate $285.8 million and unveiled a sweeping financial optimization plan that will completely eliminate all outstanding secured debt due in 2028.

Mesa Laboratories (NASDAQ:MLAB) reported a multi-fold increase in full-year net income, driven by robust demand in its core quality control and calibration divisions that successfully countered an ongoing stagnation in the global biopharmaceutical sector and structural weakness in China.

Biohaven (NYSE:BHVN) reported positive preliminary clinical data from its ongoing Phase 1b trials evaluating two novel extracellular protein degraders, hitting key biological markers and clearing a path toward advanced clinical development.

Monro (NASDAQ:MNRO) reported a 7.2% decline in fourth-quarter sales, primarily reflecting a major restructuring program that shuttered more than a hundred underperforming stores earlier in the year.

Abercrombie & Fitch (NYSE:ANF) reported record first-quarter net sales that surpassed internal projections, extending its consecutive growth streak to 14 quarters on the back of robust demand in the Asia-Pacific region.

MediWound (NASDAQ:MDWD) reported a decline in revenue for the first quarter of 2026 as the company heavily prioritized research and development funding for its late-stage clinical programs.

Bath & Body Works (NYSE:BBWI) reported a 3% decline in net sales for the first quarter of 2026, reflecting a broader normalization of consumer spending within the beauty and home fragrance categories.